Company Registry

ZeptoMetrix Corporation (AKA:Cellular Products Inc~Zeptogen Corporation)
Profile last edited on: 4/2/2021

Microorganisms for quality control
Year Founded
First SBIR Year
Latest SBIR Award
Program Status
Inactive (Acquired)


Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

878 Main Street
Buffalo, NY 14202
   (716) 882-0920
Multiple Locations:   
Congressional District:   26
County:   Erie

Public Profile

In January 2021, it was announced that ZeptoMetrix Corporation had been acquired by Cole-Palmer LLC - a developer of specialized lab and industry products. The deal wasorchestrated through that firm's backer - GTCR LLC is a private equity firm focused on leveraged buyout, leveraged recapitalization, growth capital and rollup transactions. Zeptometrix (ZMC) has functioned since 1982 as a fully integrated biotechnology facility manufacturing and distributing products for the research and biotechnology communities - having laboratories at the Roswell Park Cancer Institute enabling collaboration with scientists within the Institute on new product R&D. The firm manufacture of cytokines, cytokine support products, antibodies and AIDS testing kits for research. The cytokines produced include human platelet-derived growth factors, lymphokine recombinant human interleukin-2 (rIL-2), human T-cell growth factors (interleukin-2) and human immune interferons (Gamma IFN). The cytokine support products include gentamicin sulfate, a leukocyte isolation agent and scrubbed nylon fibers for separating leukocytes from peripheral blood. Originally - in July 1999 - Cellular Products, Inc. was purchased by ZeptoMetrix Corporation, a newly formed company established by the former management of Cellular Products, Inc.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount Project Title
2003 2 NIH $600,000
Assays for ROS Induced DNA Damage
2002 2 NIH $848,886
HTLV Supplemental Testing Device
1993 1 NIH $29,981
Surface protein of HTLV-1
1991 2 NIH $550,000
Neutralization of HIV
1989 1 NIH $50,000
Development of Elisia based reverse transcriptase assays

Key People / Management

  Carl Franzblau -- President

  Shawn R Smith -- President and Chief Executive Officer

  Harold C Box --

  Gregory R Chiklis --

  James C Hengst -- Co-Founder

  Lawrence D Papsidero --

  Karuna Sharma -- Vice President & Chief Scientific Officer

  Ronald Urmson -- Vice President & Chief - Financial Officer

  David Waterman -- Vice President, Operations

SBIR firms in the news

There are no news available.